Bfsg LLC Has $3.93 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Bfsg LLC grew its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 7.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 161,863 shares of the biopharmaceutical company's stock after buying an additional 11,733 shares during the quarter. Bfsg LLC owned 0.13% of Catalyst Pharmaceuticals worth $3,925,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in CPRX. Steward Partners Investment Advisory LLC bought a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at approximately $27,000. Park Square Financial Group LLC acquired a new position in Catalyst Pharmaceuticals during the fourth quarter worth $29,000. Farther Finance Advisors LLC raised its holdings in Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after buying an additional 1,495 shares during the last quarter. Sound Income Strategies LLC acquired a new position in Catalyst Pharmaceuticals during the first quarter worth $64,000. Finally, GAMMA Investing LLC raised its holdings in shares of Catalyst Pharmaceuticals by 26.2% in the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock valued at $68,000 after purchasing an additional 579 shares during the last quarter. 79.22% of the stock is owned by institutional investors.

Catalyst Pharmaceuticals Stock Up 0.6%

Shares of NASDAQ CPRX opened at $23.67 on Tuesday. Catalyst Pharmaceuticals, Inc. has a 52 week low of $14.75 and a 52 week high of $26.58. The firm's fifty day moving average is $23.90 and its 200 day moving average is $22.88. The company has a market cap of $2.89 billion, a price-to-earnings ratio of 20.06, a PEG ratio of 3.31 and a beta of 0.72.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Stephens restated an "overweight" rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Robert W. Baird raised their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research report on Monday, March 3rd. Wall Street Zen upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Finally, HC Wainwright restated a "buy" rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Six investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $32.83.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 44,000 shares of the business's stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $23.63, for a total transaction of $1,039,720.00. Following the sale, the insider now owns 68,873 shares in the company, valued at approximately $1,627,468.99. The trade was a 38.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Preethi Sundaram sold 1,600 shares of the company's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $26.42, for a total transaction of $42,272.00. Following the completion of the transaction, the insider now owns 41,081 shares in the company, valued at approximately $1,085,360.02. The trade was a 3.75% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 247,924 shares of company stock valued at $5,879,369. 10.40% of the stock is currently owned by company insiders.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.